SFEBES2019

09:00 - 21:00 
REGISTRATION
10:15 - 10:20 
WELCOME
Auditorium 2
10:20 - 10:50 
What Is New
Auditorium 2
Chair: Duncan Bassett (London, United Kingdom)
10:20
Auditorium 2
Session starts at 10:20
WIN1
What is New in Basic Endocrinology Research
Caroline Gorvin (Birmingham, United Kingdom)

10:35
Auditorium 2
Session starts at 10:20
WIN2
What is New in Clinical Endocrinology Research
John Newell-Price (Sheffield, United Kingdom)

11:00 - 11:05 
One Minute Silence
11:05 - 12:35 
How do I…1
Auditorium 2
Chairs: Annice Mukherjee (Salford, United Kingdom) & Channa Jayasena (London, United Kingdom)
11:05
Auditorium 2
Session starts at 11:05
HDI1.1
Management of osteoporosis in adolescence and young adults

11:20
Auditorium 2
Session starts at 11:05
HDI1.2
How do I manage an incidental finding of a thyroid nodule
Kristien Boelaert (Birmingham, United Kingdom)

11:35
Auditorium 2
Session starts at 11:05
HDI1.3
How do I decide which patients with gynaecomastia need more detailed evaluation
Sarah Ali (London, United Kingdom)

11:50
Auditorium 2
Session starts at 11:05
HDI1.4
How do I manage hair loss and hair growth in PCOS
Aled Rees (Cardiff, United Kingdom)

12:05
Auditorium 2
Session starts at 11:05
HDI1.5
How do I induce spermatogenesis
Umasuthan Srirangalingam (London, United Kingdom)

12:20
Auditorium 2
Session starts at 11:05
HDI1.6
How do I choose between drug treatments for medical weight management
Lucinda Summers (Salford, United Kingdom)

11:05 - 12:35 
Clinical Management Workshop 1: Salt & Water
Don’t be hung out ‘too’ dry
Syndicate 1 & 2
Chair: Helen Simpson (London, United Kingdom)
11:05
Syndicate 1 & 2
Session starts at 11:05
CMW1.1
Management of hyponatraemia
Steve Ball (Manchester, United Kingdom)

11:35
Syndicate 1 & 2
Session starts at 11:05
CMW1.2
Diabetes Insipidus - management challenges and pitfalls
Mark Hannon (Bantry, Ireland)

12:05
Syndicate 1 & 2
Session starts at 11:05
CMW1.3
Co-peptin- a new player in the diagnosis of salt and water balance
Mirjam Christ-Crain (Basel, Switzerland)

11:05 - 12:35 
Basic Physiology Workshop: Modelling endocrinology in vitro, in vivo & in silico
Syndicate 3 & 4
11:05
Syndicate 3 & 4
Session starts at 11:05
BPW1.1
In vivo models of endocrinology: new zebrafish models
Francesco Argenton (Padua, Italy)

11:35
Syndicate 3 & 4
Session starts at 11:05
BPW1.2
In vitro models of endocrinology: organoids from pituitary and endometrium
Hugo Vankelecom (Leuven, Belgium)

12:05
Syndicate 3 & 4
Session starts at 11:05
BPW1.3
In silico models of endocrinology: mathematical modelling of endocrine systems
Margaritis Voliotis (Exeter, United Kingdom)

12:35 - 13:55 
LUNCH, EXHIBITION, SATELLITES & POSTERS
Auditorium 1
12:45 - 13:15 
Oral Posters 1 - Adrenal and Cardiovascular
SfE Theatre
Chairs: Michael O'Reilly (Birmingham, United Kingdom) & Scott MacKenzie (Glasgow, United Kingdom)
12:50
SfE Theatre
Session starts at 12:45
OP1.1
Betamethasone/GR ChIP-Seq analysis defines a discrete set of canonical GR homodimer binding sites in primary fetal rat lung mesenchymal fibroblasts
Timothy Cole (Melbourne, Australia)

12:55
SfE Theatre
Session starts at 12:45
OP1.2
Glucocorticoids promote mitochondrial fatty acid oxidation in the fetal heart
Karen E Chapman (Edinburgh, United Kingdom)

13:00
SfE Theatre
Session starts at 12:45
OP1.3
Combining 11C-Metomidate PET/CT and 18F-FDG PET/CT – a new approach to phenotyping indeterminate adrenal lesions
Russell Senanayake (Cambridge, United Kingdom)

13:05
SfE Theatre
Session starts at 12:45
OP1.4
Global phosphoproteomics links rapidly induced cytoplasmic signals to transcriptional control
Fiona Leslie (Leeds, United Kingdom)

13:20 - 13:50 
Oral Posters 2 - Thyroid
SfE Theatre
Chairs: Carla Moran (Cambridge, United Kingdom) & Jacqueline Gilbert (London, United Kingdom)
13:25
SfE Theatre
Session starts at 13:20
OP2.1
Day case radio-iodine for remnant ablation in differentiated thyroid cancer patients is safe and helps reduce bed pressures in a busy tertiary centre hospital
Shazia Hussain (London, United Kingdom)

13:30
SfE Theatre
Session starts at 13:20
OP2.2
The SH2B3 tryptophan 262 variant is associated with Graves’ disease and Addison’s disease
Georgina Sneddon (Newcastle upon Tyne, United Kingdom)

13:35
SfE Theatre
Session starts at 13:20
OP2.3
Sustained improvements in monitoring and biochemical control of hypothyroidism in primary care with the use of an electronic protocol at two year follow up
Anh Tran (Worcester Park, United Kingdom)

13:40
SfE Theatre
Session starts at 13:20
OP2.4
The proto-oncogene PBF mediates Src modulation of radioiodine uptake
Mohammed Alshahrani (Birmingham, United Kingdom)

14:00 - 14:30 
Plenary 1:Clinical Endocrinology Trust Lecture
Auditorium 2
Chair: John Newell-Price (Sheffield, United Kingdom)
14:00
Auditorium 2
Session starts at 14:00
PL1
Controlling cortisol in cardiometabolic disease
Brian Walker (Newcastle-Upon-Tyne, United Kingdom)

14:30 - 15:00 
Plenary 2: Society for Endocrinology Starling Medal Lecture
Auditorium 2
Chair: Graham Williams (London, United Kingdom)
14:30
Auditorium 2
Session starts at 14:30
PL2
From its origins to the modern metabolic network
Markus Ralser (London, United Kingdom)

15:05 - 16:35 
Oral Communications 1 - Metabolism and Obesity
Auditorium 2
Chair: Zoi Michailidou (Edinburgh, Scotland)
15:05
Auditorium 2
Session starts at 15:05
OC1.1
Intracrine activation of 11-oxygenated androgens by AKR1C3 modulates lipid metabolism in human female adipose tissue
Lina Schiffer (Birmingham, United Kingdom)

15:20
Auditorium 2
Session starts at 15:05
OC1.2
Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism
Leanne Hodson (Oxford, United Kingdom)

15:35
Auditorium 2
Session starts at 15:05
OC1.3
Metabolic and functional effects of fatty acid overload on in vitro tissue engineered skeletal muscle.
Mark Turner (Loughborough, United Kingdom)

15:50
Auditorium 2
Session starts at 15:05
OC1.4
5β-reductase (AKR1D1) is downregulated in patients with non-alcoholic fatty liver disease and protects against hepatocellular carcinoma cell proliferation in vitro.
Nikolaos Nikolaou (Oxford, United Kingdom)

16:05
Auditorium 2
Session starts at 15:05
OC1.5
Prolyl-hydroxylase 3 maintains β-cell glucose-sensing under metabolic stress
Federica Cuozzo (Birmingham, United Kingdom)

16:20
Auditorium 2
Session starts at 15:05
OC1.6
Metabolic surgery reduces kidney SGLT2 expression in mice
Elina Akalestou (London, United Kingdom)

15:05 - 16:35 
Oral Communications 2 - Neuroendocrinology, Pituitary and Neoplasia
Syndicate 1 & 2
Chair: Chrissie Thirlwell (Exeter, United Kingdom)
15:05
Syndicate 1 & 2
Session starts at 15:05
OC2.1
Differential effects of subcutaneous pulsatile versus oral hydrocortisone replacement therapy on fMRI resting state and task based emotional processing in Patients with Primary Adrenal insufficiency
Georgina Russell (Bristol, United Kingdom)

15:20
Syndicate 1 & 2
Session starts at 15:05
OC2.2
Investigating the role of AIP in pituitary tumourigenesis
Anisha Mistry (London, United Kingdom)

15:35
Syndicate 1 & 2
Session starts at 15:05
OC2.3
ErbB receptor signalling in MCF7 breast cancer cells: an information theoretic approach
Robert J. P. Pope (Bristol, United Kingdom)

15:50
Syndicate 1 & 2
Session starts at 15:05
OC2.4
Investigating the role of vagal Y2R in PYY3-36-mediated appetite suppression
Aldara Martin Alonso (London, United Kingdom)

16:05
Syndicate 1 & 2
Session starts at 15:05
OC2.5
Efnb2 controls pituitary gland development by regulating proliferation of the pituitary stem/progenitor cells and EMT within the pituitary stem cell niche.
Angelica Gualtieri (London, United Kingdom)

16:20
Syndicate 1 & 2
Session starts at 15:05
OC2.6
Post-operative copeptin analysis as a predictor of diabetes insipidus after pituitary surgery
Hussam Rostom (Oxford, United Kingdom)

15:05 - 16:35 
Oral Communications 3 - Bone and Calcium
Syndicate 3 & 4
Chairs: Fadil Hannan (Oxford, United Kingdom) & Jennie Walsh (Sheffield, United Kingdom)
15:05
Syndicate 3 & 4
Session starts at 15:05
OC3.1
A mouse model generated by CRISPR-Cas9 with a frameshift mutation in the nuclear factor 1/X (NFIX) gene has phenotypic features reported in Marshall-Smith Syndrome (MSS) patients
Kreepa Kooblall (Oxford, United Kingdom)

15:20
Syndicate 3 & 4
Session starts at 15:05
OC3.2
Hypophosphatasia in adulthood - are patients really “unaffected”
Zhuo Min Chong (Glasgow, United Kingdom)

15:35
Syndicate 3 & 4
Session starts at 15:05
OC3.3
Generation of a long acting parathyroid hormone hybrid analogue through fusion to a binding protein
Lina Sorour (Sheffield, United Kingdom)

15:50
Syndicate 3 & 4
Session starts at 15:05
OC3.4
Characterisation of rare GNA11 variants reveals 8 novel residues important for signalling by the calcium-sensing receptor: Relevance for FHH and ADH
Anna Gluck (Oxford, United Kingdom)

16:05
Syndicate 3 & 4
Session starts at 15:05
OC3.5
Mutational analysis of a patient with familial hypocalciuric hypercalcaemia identifies a novel p.Ser182Cys mutation, which is predicted to disrupt the calcium sensing receptor (CaSR) extracellular domain
Ultan Healy (Oxford, United Kingdom)

16:20
Syndicate 3 & 4
Session starts at 15:05
OC3.6
The role of biased calcium-sensing receptor signalling in urinary calcium excretion and kidney stone disease
Michelle Goldsworthy (Oxford, United Kingdom)

16:35 - 17:05 
TEA & COFFEE
Auditorium 1
17:05 - 18:05 
Innovation Session 1: Advances in understanding skeletal disease
Syndicate 3 & 4
17:05
Syndicate 3 & 4
Session starts at 17:05
IN1.1
Identifying new skeletal disease
Outi Mäkitie (Helsinki, Finland)

17:25
Syndicate 3 & 4
Session starts at 17:05
IN1.2
Hyponatremia and osteoporosis
Joseph G. Verbalis (Washington, USA)

17:45
Syndicate 3 & 4
Session starts at 17:05
IN1.3
Bone fragility in patients with chronic kidney diseases
Martine Cohen-Solal (Paris, France)

17:05 - 18:05 
Innovation Session 2: Big data in space and time
Syndicate 1 & 2
Chair: Kathryn McGuinnis (Leeds, United Kingdom)
17:05
Syndicate 1 & 2
Session starts at 17:05
IN2.1
Single cell RNA-seq of endocrine organs
Karine Rizzoti (London, United Kingdom)

17:35
Syndicate 1 & 2
Session starts at 17:05
IN2.2
Data Science Approaches to GPCRs and Nuclear Receptors
M. Madan Babu ((Cambridge, United Kingdom))

17:05 - 18:05 
Innovation Session 3: NIHR Pathways to clinical impact
Auditorium 2
Chair: Barbara McGowan (London, United Kingdom)
17:05
Auditorium 2
Session starts at 17:05
IN3.1
From basic science to life changing therapies
Waljit Dhillo (London, United Kingdom)

17:25
Auditorium 2
Session starts at 17:05
IN3.2
Health Care Professionals, Industry and the NHS: delivering innovation
John Wilding (Liverpool, United Kingdom)

17:45
Auditorium 2
Session starts at 17:05
IN3.3
Championing Rare Disease Research
Márta Korbonits (London, United Kingdom)

18:10 - 18:40 
Plenary 3: Society for Endocrinology Dale Medal Lecture
Auditorium 2
Chair: Duncan Bassett (London, United Kingdom)
18:10
Auditorium 2
Session starts at 18:10
PL3
From Carney complex to gigantism and Cushing disease: an insight in the genetics of pituitary tumors
Constantine Stratakis (Rockville, USA)

18:40 - 19:10 
Debate: Nature vs Nurture
Auditorium 2
Chair: Rob Semple (Edinburgh, United Kingdom)
18:40
Auditorium 2
Session starts at 18:40
D1.1
AGAINST - This house believes nature not nurture determines our bodyweight
John Wilding (Liverpool, United Kingdom)

18:40
Auditorium 2
Session starts at 18:40
D1.2
FOR - This house believes nature not nurture determines our bodyweight
Sadaf Farooqi (Cambridge, United Kingdom)